Mesothelioma: Update on diagnostic strategies

Carmen M. Rosario*, Xiaoqi Lin, David William Kamp

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is a rare, highly aggressive malignancy involving the serosa of the pleura and peritoneum. The relationship between asbestos and mesothelioma was established in the 1960s; nearly a century after industrial production of asbestos began in the 1850s. Given the protean clinical manifestations and poor prognosis of MPM, a prompt, accurate diagnosis challenges clinicians in distinguishing MPM from benign asbestos pleural effusions and metastatic carcinomas. In this review, we present a patient with MPM and then review the emerging epidemiologic trends and clinical manifestations. Our primary focus is to review the accumulating evidence supporting an important role for cytopathologic immunostains and serum biomarkers in the diagnosis and management of MPM.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalClinical Pulmonary Medicine
Volume19
Issue number6
DOIs
StatePublished - Nov 1 2012

Fingerprint

Mesothelioma
Asbestos
Serous Membrane
Pleura
Peritoneum
Pleural Effusion
Biomarkers
Malignant Mesothelioma
Carcinoma
Serum
Neoplasms

Keywords

  • asbestos
  • biomarkers
  • mesothelioma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

@article{2d9f70a920c84be1997e43245f411745,
title = "Mesothelioma: Update on diagnostic strategies",
abstract = "Malignant pleural mesothelioma (MPM) is a rare, highly aggressive malignancy involving the serosa of the pleura and peritoneum. The relationship between asbestos and mesothelioma was established in the 1960s; nearly a century after industrial production of asbestos began in the 1850s. Given the protean clinical manifestations and poor prognosis of MPM, a prompt, accurate diagnosis challenges clinicians in distinguishing MPM from benign asbestos pleural effusions and metastatic carcinomas. In this review, we present a patient with MPM and then review the emerging epidemiologic trends and clinical manifestations. Our primary focus is to review the accumulating evidence supporting an important role for cytopathologic immunostains and serum biomarkers in the diagnosis and management of MPM.",
keywords = "asbestos, biomarkers, mesothelioma",
author = "Rosario, {Carmen M.} and Xiaoqi Lin and Kamp, {David William}",
year = "2012",
month = "11",
day = "1",
doi = "10.1097/CPM.0b013e318272ce61",
language = "English (US)",
volume = "19",
pages = "282--288",
journal = "Clinical Pulmonary Medicine",
issn = "1068-0640",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Mesothelioma : Update on diagnostic strategies. / Rosario, Carmen M.; Lin, Xiaoqi; Kamp, David William.

In: Clinical Pulmonary Medicine, Vol. 19, No. 6, 01.11.2012, p. 282-288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mesothelioma

T2 - Update on diagnostic strategies

AU - Rosario, Carmen M.

AU - Lin, Xiaoqi

AU - Kamp, David William

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Malignant pleural mesothelioma (MPM) is a rare, highly aggressive malignancy involving the serosa of the pleura and peritoneum. The relationship between asbestos and mesothelioma was established in the 1960s; nearly a century after industrial production of asbestos began in the 1850s. Given the protean clinical manifestations and poor prognosis of MPM, a prompt, accurate diagnosis challenges clinicians in distinguishing MPM from benign asbestos pleural effusions and metastatic carcinomas. In this review, we present a patient with MPM and then review the emerging epidemiologic trends and clinical manifestations. Our primary focus is to review the accumulating evidence supporting an important role for cytopathologic immunostains and serum biomarkers in the diagnosis and management of MPM.

AB - Malignant pleural mesothelioma (MPM) is a rare, highly aggressive malignancy involving the serosa of the pleura and peritoneum. The relationship between asbestos and mesothelioma was established in the 1960s; nearly a century after industrial production of asbestos began in the 1850s. Given the protean clinical manifestations and poor prognosis of MPM, a prompt, accurate diagnosis challenges clinicians in distinguishing MPM from benign asbestos pleural effusions and metastatic carcinomas. In this review, we present a patient with MPM and then review the emerging epidemiologic trends and clinical manifestations. Our primary focus is to review the accumulating evidence supporting an important role for cytopathologic immunostains and serum biomarkers in the diagnosis and management of MPM.

KW - asbestos

KW - biomarkers

KW - mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=84869804453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869804453&partnerID=8YFLogxK

U2 - 10.1097/CPM.0b013e318272ce61

DO - 10.1097/CPM.0b013e318272ce61

M3 - Article

C2 - 23293508

AN - SCOPUS:84869804453

VL - 19

SP - 282

EP - 288

JO - Clinical Pulmonary Medicine

JF - Clinical Pulmonary Medicine

SN - 1068-0640

IS - 6

ER -